Jupiter Neurosciences Secures $100M Term Sheet with PharmAla for U.S. Rights to NCE-Designated MDMA Compound ALA-002

Jupiter Neurosciences' move to license ALA-002 from PharmAla Biotech arrives at a moment when the regulatory and scheduling architecture around psychedelic therapeutics is shifting faster than most manufacturing organisations have prepared for. The term sheet, valued at up to $100 million inclusive of milestones and royalties, grants Jupiter exclusive, perpetual U.S. rights to a patented, non-racemic MDMA formulation that the FDA has designated as a Novel Chemical Entity (NCE), a classification that carries meaningful implications for data exclusivity, review timelines, and CDMO qualification requirements.

Under the term sheet structure, Jupiter commits an upfront payment of $3.33 million to PharmAla, $1.50 million in cash and $1.83 million in JUNS common stock subject to a 120-day lock-up, with a $600,000 escrow deposit due on execution. If a definitive agreement is not executed within 90 days of signing, the escrowed cash converts to a reverse termination fee payable to PharmAla, subject to fault-based carve-outs. Single-digit royalties and development milestone payments apply as the asset advances through approval and commercialisation.

The manufacturing context matters here. PharmAla's MDMA supply is already supporting active U.S. government-sponsored VA and DHA clinical trials, meaning GMP-compliant production processes are in place and generating real-world data. ALA-002's non-racemic formulation is engineered for improved cardiovascular safety and reduced abuse liability relative to racemic MDMA, attributes that will bear directly on the 21 CFR Part 211 documentation package and any future NDA submission, particularly around impurity profiling and process validation for a Schedule I-derived substance.

The executive order signed by President Trump on April 18, 2026, titled "Accelerating Medical Treatments for Serious Mental Illness," restructures the operating environment for any company in this space. Key provisions include a Right to Try pathway establishing Schedule I handling authorisations for treating physicians, Commissioner's National Priority Vouchers compressing review timelines to one to two months for Breakthrough Therapy-designated psychedelics, and $50 million in ARPA-H funding directed toward state and federal psychedelic medicine programmes. For QA and regulatory leads, the DEA scheduling question remains the most operationally consequential variable: expanded investigational access does not automatically resolve the controlled substance manufacturing and distribution controls that CDMOs and site heads must satisfy under current DEA registration frameworks.

The definitive agreement, if executed within the 90-day window, will set the formal timeline for IND advancement and the process validation milestones that will determine how quickly ALA-002 can move toward a pivotal programme.

Source: GlobeNewswire via PharmAla Biotech / Jupiter Neurosciences press release, May 20, 2026.